Lista de obras -

A revised international prognostic score system for Waldenström's macroglobulinemia

artículo científico publicado en 2019

Anti-BCMA antibodies in the future management of multiple myeloma

scientific article published on 18 March 2019

Antibody therapies for multiple myeloma

artículo científico publicado en 2020

BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years

artículo científico publicado en 2016

Bone marrow biopsy in low-risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group

scientific article published on 06 March 2019

Bortezomib as a treatment option in patients with Waldenström macroglobulinemia

artículo científico publicado en 2010

Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis.

artículo científico publicado en 2016

COVID-19: time to flatten the infodemic curve

artículo científico publicado en 2021

Cardiac and renal complications of carfilzomib in patients with multiple myeloma

artículo científico publicado en 2017

Carfilzomib-associated renal toxicity is common and unpredictable: a comprehensive analysis of 114 multiple myeloma patients

scientific article published on 03 November 2020

Cell-free DNA analysis for the detection of MYD88 and CXCR4 mutations in IgM monoclonal gammopathies; an update with clinicopathological correlations

scientific article published on 03 April 2020

Characterization of a PERK Kinase Inhibitor with Anti-Myeloma Activity

artículo científico publicado en 2020

Cholangiocarcinoma: investigations into pathway-targeted therapies

artículo científico publicado en 2020

Circulating Soluble Receptor Activator of Nuclear Factor Kappa B Ligand and C-C Motif Ligand 3 Correlate With Survival in Patients With Waldenström Macroglobulinemia

artículo científico publicado en 2018

Circulating Soluble Urokinase-Type Plasminogen Activator Receptor Levels Reflect Renal Function in Newly Diagnosed Patients with Multiple Myeloma Treated with Bortezomib-Based Induction

artículo científico publicado en 2020

Clinical Utility of Selinexor/Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma: A Review of Current Evidence and Patient Selection

scientific article published on 01 July 2020

Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens

artículo científico publicado en 2013

Clinical and prognostic significance of serum levels of von Willebrand factor and ADAMTS-13 antigens in AL amyloidosis

artículo científico publicado en 2016

Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents

scientific article published on 14 April 2020

Coexistence of leishmaniasis and multiple myeloma in the era of monoclonal antibody (anti-CD38 or anti-SLAMF7) containing triplets: one shared story of two exceptional cases

Competing risk survival analysis in patients with symptomatic Waldenström macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy

artículo científico publicado en 2015

Consolidation therapy with the combination of bortezomib and lenalidomide (VR) without dexamethasone in multiple myeloma patients after transplant: Effects on survival and bone outcomes in the absence of bisphosphonates

artículo científico publicado en 2019

Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with mu

artículo científico publicado en 2020

Correction to: Current Approaches in the Management of Hepatic Adenomas

artículo científico publicado en 2020

Current Approaches in the Management of Hepatic Adenomas

Current treatment options and investigational drugs for Waldenstrom's Macroglobulinemia

artículo científico publicado en 2017

Current treatments for renal failure due to multiple myeloma

artículo científico publicado en 2016

Daratumumab-based therapy for patients with monoclonal gammopathy of renal significance

scientific article published on 23 August 2020

Deep Phenotyping Reveals Distinct Immune Signatures Correlating with Prognostication, Treatment Responses, and MRD Status in Multiple Myeloma

scientific article published on 04 November 2020

Detection of MYD88 and CXCR4 mutations in cell-free DNA of patients with IgM monoclonal gammopathies

artículo científico publicado en 2018

Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenstrom macroglobulinemia: final analysis of a phase 2 study

article

Diffuse pattern of bone marrow involvement on magnetic resonance imaging is associated with high risk cytogenetics and poor outcome in newly diagnosed, symptomatic patients with multiple myeloma: a single center experience on 228 patients

artículo científico publicado en 2012

Disappearing liver metastases: A systematic review of the current evidence

artículo científico publicado en 2019

Dynamic contrast-enhanced magnetic resonance imaging parameters correlate with advanced revised-ISS and angiopoietin-1/angiopoietin-2 ratio in patients with multiple myeloma.

artículo científico publicado en 2017

Effect of induction therapy with lenalidomide, doxorubicin and dexamethasone on bone remodeling and angiogenesis in newly diagnosed multiple myeloma

scientific article published on 22 January 2019

Efficacy and safety of elotuzumab for the treatment of multiple myeloma

artículo científico publicado en 2017

Efficacy of lenalidomide as salvage therapy for patients with AL amyloidosis

artículo científico publicado en 2018

Elevated vWF Antigen Serum Levels Are Associated With Poor Prognosis, and Decreased Circulating ADAMTS-13 Antigen Levels Are Associated With Increased IgM Levels and Features of WM but not Increased vWF Levels in Patients With Symptomatic WM

artículo científico publicado en 2018

Elotuzumab in combination with pomalidomide and dexamethasone for the treatment of multiple myeloma

scientific article published on 04 November 2019

Emerging Insights Into the Role of the Hippo Pathway in Multiple Myeloma and Associated Bone Disease

scientific article published on 09 October 2019

Emerging treatment approaches for myeloma-related bone disease

artículo científico publicado en 2017

Emerging treatment strategies for COVID-19 infection

artículo científico publicado en 2020

European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias

artículo científico publicado en 2018

Evaluating ibrutinib in the treatment of symptomatic Waldenstrom's macroglobulinemia

scientific article published on 27 August 2019

Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis.

artículo científico publicado en 2018

Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma

artículo científico publicado en 2016

Expression of CCL3 by Neoplastic Cells in Patients with Waldenström's Macroglobulinemia: An Immunohistochemical Study in Bone Marrow Biopsies of 67 Patients

artículo científico publicado en 2011

Genetic factors related with early onset of osteonecrosis of the jaw in patients with multiple myeloma under zoledronic acid therapy

artículo científico publicado en 2017

Growth Differentiation Factor 15 Is a New Biomarker for Survival and Renal Outcomes in Light Chain (AL) Amyloidosis

artículo científico publicado en 2018

Hematologic and renal improvement of monoclonal immunoglobulin deposition disease after treatment with bortezomib-based regimens.

artículo científico publicado en 2016

High levels of periostin correlate with increased fracture rate, diffuse MRI pattern, abnormal bone remodeling and advanced disease stage in patients with newly diagnosed symptomatic multiple myeloma

artículo científico publicado en 2016

High levels of serum TIMP-1 correlate with advanced disease and predict for poor survival in patients with multiple myeloma treated with novel agents

artículo científico publicado en 2009

High levels of serum angiogenic growth factors in patients with AL amyloidosis: comparisons with normal individuals and multiple myeloma patients

How I treat elderly patients with plasma cell dyscrasias

scientific article published on 01 December 2018

Increased expression of cyclin-D1 on trephine bone marrow biopsies independently predicts for shorter overall survival in patients with multiple myeloma treated with novel agents

scholarly article by Anna Tasidou et al published 6 May 2012 in American Journal of Hematology

Involvement of small nerve fibres and autonomic nervous system in AL amyloidosis: comprehensive characteristics and clinical implications

artículo científico publicado en 2020

Lack of survival improvement with novel anti-myeloma agents for patients with multiple myeloma and central nervous system involvement: the Greek Myeloma Study Group experience

artículo científico publicado en 2015

Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment

artículo científico publicado en 2010

Lenalidomide in patients with POEMS syndrome: a systematic review and pooled analysis.

artículo científico publicado en 2014

Lenalidomide with low- or intermediate-dose dexamethasone in patients with relapsed or refractory myeloma

Lenalidomide-associated pneumonitis in patients with plasma cell dyscrasias

artículo científico publicado en 2011

Long PFS of more than 7 years is achieved in 9% of myeloma patients in the era of conventional chemotherapy and of first-generation novel anti-myeloma agents: a single-center experience over 20-year period

artículo científico publicado en 2020

Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies

artículo científico publicado en 2015

Longer procoagulant phospholipid-dependent clotting time, lower endogenous thrombin potential and higher tissue factor pathway inhibitor concentrations are associated with increased VTE occurrence in patients with newly diagnosed multiple myeloma: re

artículo científico publicado en 2018

Management of multiple myeloma bone disease: impact of treatment on renal function

artículo científico publicado en 2018

Meat, fish, dairy products and risk of hematological malignancies in adults - a systematic review and meta-analysis of prospective studies

scientific article published on 26 March 2019

Mechanisms of bone destruction in multiple myeloma

artículo científico publicado en 2017

Multiple Myeloma and Thrombosis: Prophylaxis and Risk Prediction Tools

scientific article published on 13 January 2020

Multiple myeloma: Role of autologous transplantation

artículo científico publicado en 2019

Neutrophil Gelatinase--Associated Lipocalin and Cystatin C Are Sensitive Markers of Renal Injury in Patients With Multiple Myeloma

artículo científico publicado en 2015

Next generation flow cytometry for MRD detection in patients with AL amyloidosis

artículo científico publicado en 2020

No significant improvement in the outcome of patients with Waldenström's macroglobulinemia treated over the last 25 years

scientific article published on 20 April 2011

Optimizing therapy in bortezomib-exposed patients with multiple myeloma

artículo científico publicado en 2018

Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma

artículo científico publicado en 2019

Organ-specific manifestations of COVID-19 infection

artículo científico publicado en 2020

Peripheral Blood Immune Profiling of Convalescent Plasma Donors Reveals Alterations in Specific Immune Subpopulations Even at 2 Months Post SARS-CoV-2 Infection

artículo científico publicado en 2020

Phase 2 study of ofatumumab, fludarabine and cyclophosphamide in relapsed/refractory Waldenström’s macroglobulinemia

Primary plasma cell leukemia presenting as secondary pulmonary alveolar proteinosis

scientific article published on 13 May 2020

Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN).

artículo científico publicado en 2013

Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone

artículo científico publicado en 2019

Prognostication of the High-Risk WM Patient

artículo científico publicado en 2011

Progression Risk Stratification of Asymptomatic Waldenström Macroglobulinemia

artículo científico publicado en 2019

Prophylactic antibiotics for the prevention of neutropenic fever in patients undergoing autologous stem-cell transplantation: results of a single institution, randomized phase 2 trial

artículo científico publicado en 2010

Pulmonary function abnormalities are common in patients with multiple myeloma and are independently associated with worse outcome

artículo científico publicado en 2019

Reactive Vasodilation Predicts Mortality in Primary Systemic Light-Chain Amyloidosis

artículo científico publicado en 2019

Real-world data on incidence, clinical characteristics and outcome of patients with macrofocal multiple myeloma (MFMM) in the era of novel therapies: A study of the Greco-Israeli collaborative myeloma working group

artículo científico publicado en 2020

Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma

scientific article published on 01 April 2020

Renal outcomes in patients with AL amyloidosis: Prognostic factors, renal response and the impact of therapy

artículo científico publicado en 2017

Renal pathology in patients with monoclonal gammopathy or multiple myeloma: monoclonal immunoglobulins are not always the cause

artículo científico publicado en 2020

Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents

artículo científico publicado en 2010

Rituximab-based treatments in Waldenström's macroglobulinemia

scientific article published on March 2009

Screening for Gaucher disease among patients with plasma cell dyscrasias

artículo científico publicado en 2019

Semaphorin 4D correlates with increased bone resorption, hypercalcemia, and disease stage in newly diagnosed patients with multiple myeloma.

artículo científico publicado en 2018

Short progression-free survival predicts for poor overall survival in older patients with multiple myeloma treated upfront with novel agent-based therapy

TLR4/TIRAP polymorphisms are associated with progression and survival of patients with symptomatic myeloma

artículo científico publicado en 2015

The Role of Low Dose Whole Body CT in the Detection of Progression of Patients with Smoldering Multiple Myeloma

scientific article published on 25 September 2020

The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents

artículo científico publicado en 2017

The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed/refractory multiple myeloma but has no effect on bone formation: Final results on 205 patients of the Greek myeloma study group

scholarly article by Evangelos Terpos et al published 15 October 2013 in American Journal of Hematology

The current role of BTK inhibitors in the treatment of Waldenstrom's Macroglobulinemia

scientific article published on 13 July 2020

Timing and impact of a deep response in the outcome of patients with systemic light chain (AL) amyloidosis

artículo científico publicado en 2020

Toll-Like Receptor 4 Activation Promotes Multiple Myeloma Cell Growth and Survival Via Suppression of The Endoplasmic Reticulum Stress Factor Chop

artículo científico publicado en 2019

Treatment of Bing-Neel syndrome with first line sequential chemoimmunotherapy: A case report

artículo científico publicado en 2019

Treatment of light chain deposition disease with bortezomib and dexamethasone

artículo científico publicado en 2009

Updates on thrombotic events associated with multiple myeloma

scientific article published on 14 April 2019

VTD consolidation, without bisphosphonates, reduces bone resorption and is associated with a very low incidence of skeletal-related events in myeloma patients post ASCT.

artículo científico publicado en 2013

Validation of the International Prognostic Scoring System (IPSS) for Waldenstrom's macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH)

artículo científico publicado en 2010

Vulnerability variables among octogenerian myeloma patients: a single-center analysis of 110 patients

scientific article published on 10 January 2019

Lista de obras de

A revised international prognostic score system for Waldenström's macroglobulinemia

Anti-BCMA antibodies in the future management of multiple myeloma

Antibody therapies for multiple myeloma

BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years

Bone marrow biopsy in low-risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group

Bortezomib as a treatment option in patients with Waldenström macroglobulinemia

Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis.

COVID-19: time to flatten the infodemic curve

Cardiac and renal complications of carfilzomib in patients with multiple myeloma

Carfilzomib-associated renal toxicity is common and unpredictable: a comprehensive analysis of 114 multiple myeloma patients

Cell-free DNA analysis for the detection of MYD88 and CXCR4 mutations in IgM monoclonal gammopathies; an update with clinicopathological correlations

Characterization of a PERK Kinase Inhibitor with Anti-Myeloma Activity

Cholangiocarcinoma: investigations into pathway-targeted therapies

Circulating Soluble Receptor Activator of Nuclear Factor Kappa B Ligand and C-C Motif Ligand 3 Correlate With Survival in Patients With Waldenström Macroglobulinemia

Circulating Soluble Urokinase-Type Plasminogen Activator Receptor Levels Reflect Renal Function in Newly Diagnosed Patients with Multiple Myeloma Treated with Bortezomib-Based Induction

Clinical Utility of Selinexor/Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma: A Review of Current Evidence and Patient Selection

Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens

Clinical and prognostic significance of serum levels of von Willebrand factor and ADAMTS-13 antigens in AL amyloidosis

Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents

Coexistence of leishmaniasis and multiple myeloma in the era of monoclonal antibody (anti-CD38 or anti-SLAMF7) containing triplets: one shared story of two exceptional cases

Competing risk survival analysis in patients with symptomatic Waldenström macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy

Consolidation therapy with the combination of bortezomib and lenalidomide (VR) without dexamethasone in multiple myeloma patients after transplant: Effects on survival and bone outcomes in the absence of bisphosphonates

Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with mu

Correction to: Current Approaches in the Management of Hepatic Adenomas

Current Approaches in the Management of Hepatic Adenomas

Current treatment options and investigational drugs for Waldenstrom's Macroglobulinemia

Current treatments for renal failure due to multiple myeloma

Daratumumab-based therapy for patients with monoclonal gammopathy of renal significance

Deep Phenotyping Reveals Distinct Immune Signatures Correlating with Prognostication, Treatment Responses, and MRD Status in Multiple Myeloma

Detection of MYD88 and CXCR4 mutations in cell-free DNA of patients with IgM monoclonal gammopathies

Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenstrom macroglobulinemia: final analysis of a phase 2 study

Diffuse pattern of bone marrow involvement on magnetic resonance imaging is associated with high risk cytogenetics and poor outcome in newly diagnosed, symptomatic patients with multiple myeloma: a single center experience on 228 patients

Disappearing liver metastases: A systematic review of the current evidence

Dynamic contrast-enhanced magnetic resonance imaging parameters correlate with advanced revised-ISS and angiopoietin-1/angiopoietin-2 ratio in patients with multiple myeloma.

Effect of induction therapy with lenalidomide, doxorubicin and dexamethasone on bone remodeling and angiogenesis in newly diagnosed multiple myeloma

Efficacy and safety of elotuzumab for the treatment of multiple myeloma

Efficacy of lenalidomide as salvage therapy for patients with AL amyloidosis

Elevated vWF Antigen Serum Levels Are Associated With Poor Prognosis, and Decreased Circulating ADAMTS-13 Antigen Levels Are Associated With Increased IgM Levels and Features of WM but not Increased vWF Levels in Patients With Symptomatic WM

Elotuzumab in combination with pomalidomide and dexamethasone for the treatment of multiple myeloma

Emerging Insights Into the Role of the Hippo Pathway in Multiple Myeloma and Associated Bone Disease

Emerging treatment approaches for myeloma-related bone disease

Emerging treatment strategies for COVID-19 infection

European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias

Evaluating ibrutinib in the treatment of symptomatic Waldenstrom's macroglobulinemia

Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis.

Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma

Expression of CCL3 by Neoplastic Cells in Patients with Waldenström's Macroglobulinemia: An Immunohistochemical Study in Bone Marrow Biopsies of 67 Patients

Genetic factors related with early onset of osteonecrosis of the jaw in patients with multiple myeloma under zoledronic acid therapy

Growth Differentiation Factor 15 Is a New Biomarker for Survival and Renal Outcomes in Light Chain (AL) Amyloidosis

Hematologic and renal improvement of monoclonal immunoglobulin deposition disease after treatment with bortezomib-based regimens.

High levels of periostin correlate with increased fracture rate, diffuse MRI pattern, abnormal bone remodeling and advanced disease stage in patients with newly diagnosed symptomatic multiple myeloma

High levels of serum TIMP-1 correlate with advanced disease and predict for poor survival in patients with multiple myeloma treated with novel agents

High levels of serum angiogenic growth factors in patients with AL amyloidosis: comparisons with normal individuals and multiple myeloma patients

How I treat elderly patients with plasma cell dyscrasias

Increased expression of cyclin-D1 on trephine bone marrow biopsies independently predicts for shorter overall survival in patients with multiple myeloma treated with novel agents

Involvement of small nerve fibres and autonomic nervous system in AL amyloidosis: comprehensive characteristics and clinical implications

Lack of survival improvement with novel anti-myeloma agents for patients with multiple myeloma and central nervous system involvement: the Greek Myeloma Study Group experience

Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment

Lenalidomide in patients with POEMS syndrome: a systematic review and pooled analysis.

Lenalidomide with low- or intermediate-dose dexamethasone in patients with relapsed or refractory myeloma

Lenalidomide-associated pneumonitis in patients with plasma cell dyscrasias

Long PFS of more than 7 years is achieved in 9% of myeloma patients in the era of conventional chemotherapy and of first-generation novel anti-myeloma agents: a single-center experience over 20-year period

Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies

Longer procoagulant phospholipid-dependent clotting time, lower endogenous thrombin potential and higher tissue factor pathway inhibitor concentrations are associated with increased VTE occurrence in patients with newly diagnosed multiple myeloma: re

Management of multiple myeloma bone disease: impact of treatment on renal function

Meat, fish, dairy products and risk of hematological malignancies in adults - a systematic review and meta-analysis of prospective studies

Mechanisms of bone destruction in multiple myeloma

Multiple Myeloma and Thrombosis: Prophylaxis and Risk Prediction Tools

Multiple myeloma: Role of autologous transplantation

Neutrophil Gelatinase--Associated Lipocalin and Cystatin C Are Sensitive Markers of Renal Injury in Patients With Multiple Myeloma

Next generation flow cytometry for MRD detection in patients with AL amyloidosis

No significant improvement in the outcome of patients with Waldenström's macroglobulinemia treated over the last 25 years

Optimizing therapy in bortezomib-exposed patients with multiple myeloma

Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma

Organ-specific manifestations of COVID-19 infection

Peripheral Blood Immune Profiling of Convalescent Plasma Donors Reveals Alterations in Specific Immune Subpopulations Even at 2 Months Post SARS-CoV-2 Infection

Phase 2 study of ofatumumab, fludarabine and cyclophosphamide in relapsed/refractory Waldenström’s macroglobulinemia

Primary plasma cell leukemia presenting as secondary pulmonary alveolar proteinosis

Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN).